Skip to main content
. 2019 May 15;10:2042098619847420. doi: 10.1177/2042098619847420

Figure 4.

Figure 4.

2016 Survey: Main sources of information for learning about the risks associated with golimumab among golimumab prescribers for all surveyed countries and all specialties combined. Data are shown as the percentage of golimumab prescriber healthcare professionals surveyed (N = 439).